Is Spectrum Pharmaceuticals, Inc. Blazing the Comeback Trail?

Spectrum Pharmaceuticals has been one of the rare losers in the biopharma sector. That trend may be set to change, however, as the company has set itself up for long-term growth.

Feb 10, 2014 at 8:30AM

Wall Street isn't a big fan of Spectrum Pharmaceuticals (NASDAQ:SPPI). Presently, 23% of the shares are being sold short and the company's stock has lost over a third of its value in the last year alone.

Spectrum's fall during a time when the entire biotech sector has been soaring seems odd. However, the Street's pessimism does have logic on its side. At the start of last year, generic competition cut deep into the sales of the company's lead cancer drug Fusilev, reducing revenue by nearly half. To top it off, Spectrum raised $120 million through a convertible debt instrument that sent shares tumbling last December.

Even so, my view is that the tide could be turning at Spectrum. As such, the abiding pessimism surrounding the stock might be providing investors a chance to buy shares on the cheap.

Why is Spectrum a turnaround candidate?
First, the company has been making significant progress on the clinical front, headed by the recent New Drug Application, or NDA, with the U.S. Food and Drug Administration, or FDA, for Beleodaq.

Beleodaq is an experiment lymphoma drug set to be reviewed by the FDA by Aug. 9. The FDA also gave the drug priority review, meaning the agency believes Beleodaq could be a significant improvement in the treatment of a serious condition. While this expedited regulatory review doesn't guarantee an approval, it certainly doesn't hurt things.

Secondly, Spectrum has bolstered its commercial pipeline through recent acquisitions. In particular, the company acquired Marqibo through its acquisition of Talon Pharmaceuticals last July. Marqibo is an orphan drug approved for the treatment of a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

The problem is that the market potential of Marqibo is still up in the air. Strict on-label use should generate around $100 million a year in sales. However, off-label use of Marqibo could potentially drive peak sales over a billion a year. Given that Spectrum has a market cap of only $500 at the time of writing this article, I think it's safe to say that the market hasn't factored Mariqbo sales under either scenario.

Turning to Spectrum's clinical pipeline, the company has two other late-stage candidates under development. Of particular interest is Spectrum's experimental treatment for multiple myeloma in a transplant setting called melphalan. Melphalan has received orphan drug status and should be submitted for regulatory review before the end of 2014.

In terms of market potential, investors should look toward Takeda Pharmaceuticals' Velcade and Celgene's (NASDAQ:CELG) Revlimid. Put simply, melphalan has the potential to see sales in the $500 to $800 million range, depending on the influence of competition within the multiple myeloma space.  

In sum, Spectrum has a number of irons in the fire so to speak, giving it a good chance to make a strong comeback this year.

Why did Spectrum fail to rally following Beleodaq's NDA?
Investors appear to be confused over why Spectrum shares rose 6% immediately following the FDA's acceptance of Beleodaq's NDA but ended up finishing the week down 2.62% overall. I believe the answer is partly because Beleodaq would compete with one of Spectrum's other approved drugs, Folotyn. Folotyn has been a commercial disappoint for the most part, and is expected to generate only a tad over $40 million in revenue this year. Beleodaq's approval would thus cut deeper into Folotyn's already tenuous market share.  

More globally, new drugs for relapsed or refractory peripheral T-cell lymphoma face an uncertain financial future in general, because a number of chemotherapies, as well as treatment combos, already exist. And because only 26% of patients responded to treatment with Beleodaq in clinical trials, I wouldn't expect it to make alternative modalities obsolete.

Beleodaq's commercial prospects get even worse when considering that antibody drug conjugates like Seattle Genetic's (NASDAQ:SGEN) Adcetris appear to be gaining traction as the preferred treatment for cancers like T-cell lymphoma. In short, it's unclear how much impact Beleodaq's approval would have on Spectrum's bottom line over the long-term.

Foolish takeaways
I think Spectrum shares have excellent upside potential over the long term. By that, I mean three to five years minimum. In the near-term, the market will probably continue to discount Spectrum's potential for a couple of reasons.

First, Beleodaq doesn't appear to be a major revenue generator, and it conflicts with other products in the company's commercial portfolio. Secondly, Marqibo is still very early into its commercial launch, and its maximum revenue potential won't be known for a long time. Finally, melphalan probably won't hit the market until the fourth quarter of 2015, if it's approved.

That said, Spectrum does offer investors multiple avenues for share price appreciation. So, you may want to dig deeper into this intriguing cancer specialist.   

Spectrum Pharmaceuticals may have upside potential, but this stock looks even better
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Celgene and Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers